{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:39:27Z","timestamp":1792791567300,"version":"4.5.0"},"reference-count":176,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.breast.2026.104946","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:06:37Z","timestamp":1792249597000},"page":"104946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Current state and future potential of radiopharmaceutical therapy in breast cancer"],"prefix":"10.1016","volume":"90","author":[{"given":"Joyce","family":"O'Shaughnessy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1349-9774","authenticated-orcid":false,"given":"Neil K.","family":"Taunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7953-0113","authenticated-orcid":false,"given":"Gary A.","family":"Ulaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104946_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1321654","article-title":"Editorial: heterogeneity in breast cancer: clinical and therapeutic implications","volume":"14","author":"Carlino","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.breast.2026.104946_bib2","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1021\/bc200151q","article-title":"Theranostics: combining imaging and therapy","volume":"22","author":"Kelkar","year":"2011","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.breast.2026.104946_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114538","article-title":"Imaging-guided targeted radionuclide tumor therapy: from concept to clinical translation","volume":"190","author":"Sun","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.breast.2026.104946_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.semradonc.2020.07.002","article-title":"The radiobiology of radiopharmaceuticals","volume":"31","author":"Morris","year":"2021","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.breast.2026.104946_bib5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.breast.2026.104946_bib6","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.3390\/molecules27103062","article-title":"The chemical scaffold of theranostic radiopharmaceuticals: radionuclide, bifunctional chelator, and pharmacokinetics modifying linker","volume":"27","author":"Holik","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.breast.2026.104946_bib7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annonc.2023.03.001","article-title":"Next generation radiotheranostics promoting precision medicine","volume":"34","author":"Pomykala","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104946_bib8","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.3390\/molecules27175429","article-title":"Radionuclides for targeted therapy: physical properties","volume":"27","author":"Stokke","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.breast.2026.104946_bib9","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.3390\/ijms23095023","article-title":"Radiopharmaceuticals for PET and SPECT imaging: a literature review over the last decade","volume":"23","author":"Cri\u015fan","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.breast.2026.104946_bib10","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20221153","article-title":"The current role of nuclear medicine in breast cancer","volume":"96","author":"Vaz","year":"2023","journal-title":"Br J Radiol"},{"key":"10.1016\/j.breast.2026.104946_bib11","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.7150\/thno.96675","article-title":"Theranostics - a sure cure for cancer after 100 years?","volume":"14","author":"Song","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.breast.2026.104946_bib12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4274\/ejbh.galenos.2021.2021-3-4","article-title":"Treatment with radiopharmaceuticals and radionuclides in breast cancer: current options","volume":"17","author":"Altiparmak G\u00fcle\u00e7","year":"2021","journal-title":"Eur J Breast Health"},{"key":"10.1016\/j.breast.2026.104946_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-024-02041-6","article-title":"Radiopharmaceuticals and their applications in medicine","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.breast.2026.104946_bib14","doi-asserted-by":"crossref","DOI":"10.1148\/rycan.220157","article-title":"A review of theranostics: perspectives on emerging approaches and clinical advancements","volume":"5","author":"Burkett","year":"2023","journal-title":"Radiol Imaging Cancer"},{"key":"10.1016\/j.breast.2026.104946_bib15","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2533\/chimia.2020.939","article-title":"Targeted radiotherapeutics from 'bench-to-bedside'","volume":"74","author":"M\u00fcller","year":"2020","journal-title":"Chimia (Aarau)"},{"key":"10.1016\/j.breast.2026.104946_bib16","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3390\/pharmaceutics16111458","article-title":"Optimization processes of clinical chelation-based radiopharmaceuticals for pathway-directed targeted radionuclide therapy in oncology","volume":"16","author":"Tomiyoshi","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.breast.2026.104946_bib17","article-title":"Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists","volume":"9","author":"Shi","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.breast.2026.104946_bib18","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.7150\/thno.96403","article-title":"Actinium-225 targeted alpha particle therapy for prostate cancer","volume":"14","author":"Bidkar","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.breast.2026.104946_bib19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00259-025-07390-0","article-title":"Targeted alpha therapy: a comprehensive analysis of the biological effects from \"local-regional-systemic\" dimensions","volume":"53","author":"Song","year":"2025","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.breast.2026.104946_bib20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.nucmedbio.2021.03.002","article-title":"Auger: the future of precision medicine","volume":"96\u201397","author":"Pirovano","year":"2021","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.breast.2026.104946_bib21","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.3390\/ijms22094597","article-title":"Theranostic advances in breast cancer in nuclear medicine","volume":"22","author":"Vahidfar","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.breast.2026.104946_bib22","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1631\/jzus.B1400131","article-title":"Therapeutic radionuclides in nuclear medicine: current and future prospects","volume":"15","author":"Yeong","year":"2014","journal-title":"J Zhejiang Univ - Sci B"},{"key":"10.1016\/j.breast.2026.104946_bib23","first-page":"7","article-title":"Radiation","volume":"100","year":"2012","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"key":"10.1016\/j.breast.2026.104946_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13550-023-00995-2","article-title":"Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications","volume":"13","author":"Altena","year":"2023","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.breast.2026.104946_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102304","article-title":"Currents status of radiotracers for breast cancer imaging in PET","volume":"53","author":"Jean","year":"2025","journal-title":"Transl Oncol"},{"key":"10.1016\/j.breast.2026.104946_bib26","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3390\/ijms25031575","article-title":"Imaging molecular targets and metabolic pathways in breast cancer for improved clinical management: current practice and future perspectives","volume":"25","author":"Ndlovu","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.breast.2026.104946_bib27","first-page":"692","article-title":"Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET","volume":"38","author":"Kole","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2026.104946_bib28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2967\/jnumed.117.193888","article-title":"Tumor uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic\u00a0Breast Cancer","volume":"59","author":"Mortimer","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2026.104946_bib29","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2967\/jnumed.123.265486","article-title":"Initial evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions","volume":"64","author":"Watabe","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2026.104946_bib30","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics in oncology: current challenges and emerging opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.breast.2026.104946_bib31","series-title":"Theranostics, a new innovative approach to cancer treatment","author":"Bom","year":"2024"},{"key":"10.1016\/j.breast.2026.104946_bib32","first-page":"333","article-title":"Molecular imaging in oncology: current impact and future directions","volume":"72","author":"Rowe","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.breast.2026.104946_bib33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1515\/oncologie-2024-0543","article-title":"Role of emerging theranostic technologies in precision oncology: revolutionizing cancer diagnosis and treatment","volume":"27","author":"Ayalew","year":"2025","journal-title":"Oncologie"},{"key":"10.1016\/j.breast.2026.104946_bib34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.61838\/kman.hn.2.1.6","article-title":"Advances in radiological techniques for cancer diagnosis: a narrative review of current technologies","volume":"2","author":"Ali","year":"2024","journal-title":"Health Nexus"},{"key":"10.1016\/j.breast.2026.104946_bib35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7150\/ntno.64141","article-title":"Radiotheranostics - precision medicine in nuclear medicine and molecular imaging","volume":"6","author":"Duan","year":"2022","journal-title":"Nanotheranostics"},{"key":"10.1016\/j.breast.2026.104946_bib36","series-title":"NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (v1.2026)","year":"2026"},{"key":"10.1016\/j.breast.2026.104946_bib37","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1007\/s00259-024-06758-y","article-title":"The EANM-SNMMI guideline on the role of [18F]FDG-PET\/CT in breast cancer: important milestones and perspectives for the future","volume":"51","author":"Hindi\u00e9","year":"2024","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.breast.2026.104946_bib38","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(24)00054-0","article-title":"3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial","volume":"403","author":"P\u00e9rez-Garc\u00eda","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2026.104946_bib39","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1007\/s00259-024-06696-9","article-title":"Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET\/CT in no special type breast cancer: (endorsed by the ACR, ESSO, ESTRO, EUSOBI\/ESR, and EUSOMA)","volume":"51","author":"Vaz","year":"2024","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.breast.2026.104946_bib40","series-title":"CERIANNA","article-title":"Zionexa US Corp","year":"2020"},{"key":"10.1016\/j.breast.2026.104946_bib41","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2967\/jnumed.123.266938","article-title":"Summary: SNMMI Procedure Standard\/EANM Practice Guideline for estrogen receptor imaging of patients with breast cancer using 16\u03b1-[18F]Fluoro-17\u03b2-Estradiol PET","volume":"65","author":"Mankoff","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2026.104946_bib42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2967\/jnumed.123.265420","article-title":"Summary: appropriate use criteria for estrogen receptor\u2013targeted PET imaging with 16\u03b1-18F-Fluoro-17\u03b2-Fluoroestradiol","volume":"64","author":"Ulaner","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2026.104946_bib43","series-title":"LUTATHERA","year":"2024"},{"key":"10.1016\/j.breast.2026.104946_bib44","series-title":"PLUVICTO\u00ae (lutetium Lu 177 vipivotide tetraxetan)","year":"2025"},{"key":"10.1016\/j.breast.2026.104946_bib45","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejphar.2009.05.035","article-title":"Endoradiotherapy in cancer treatment \u2014 basic concepts and future trends","volume":"625","author":"Zoller","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.breast.2026.104946_bib46","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/genes15070903","article-title":"A comprehensive review of HER2 in cancer biology and therapeutics","volume":"15","author":"Cheng","year":"2024","journal-title":"Genes"},{"key":"10.1016\/j.breast.2026.104946_bib47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5858\/2010-0454-RAR.1","article-title":"HER2: biology, detection, and clinical implications","volume":"135","author":"Gutierrez","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.breast.2026.104946_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000279","article-title":"Activating HER2 mutations as emerging targets in multiple solid cancers","volume":"2","author":"Connell","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104946_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241612795","article-title":"Low and ultra-low HER2 in human breast cancer: an effort to define new neoplastic subtypes","volume":"24","author":"Franchina","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.breast.2026.104946_bib50","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038508","article-title":"HER2\/PI3K\/AKT pathway in HER2-positive breast cancer: a review","volume":"103","author":"Pan","year":"2024","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.breast.2026.104946_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.breast.2026.104946_bib52","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104946_bib53","series-title":"ENHERTU","year":"2025"},{"key":"10.1016\/j.breast.2026.104946_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102940","article-title":"Radioligand therapy in metastatic breast cancer: harnessing precision oncology","volume":"136","author":"Giugliano","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2026.104946_bib55","series-title":"20th Annual Meeting of the European Society for Molecular Imaging Bilbao, Spain","article-title":"Use of radioactive labeled single domain antibodies in HER2-positive cancer","author":"Altunay","year":"2025"},{"key":"10.1016\/j.breast.2026.104946_bib56","article-title":"Theranostic pair of affibody molecules targeting HER2 expressing cancer","volume":"66","author":"Wuerth","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2026.104946_bib57","series-title":"Physiology, somatostatin. StatPearls. Treasure Island (FL)","author":"O'Toole","year":"2025"},{"key":"10.1016\/j.breast.2026.104946_bib58","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1053\/j.gastro.2010.07.002","article-title":"Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy","volume":"139","author":"Oberg","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.breast.2026.104946_bib59","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3390\/biomedicines12030578","article-title":"The state-of-the-art mechanisms and antitumor effects of somatostatin in colorectal cancer: a review","volume":"12","author":"Kasprzak","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.breast.2026.104946_bib60","doi-asserted-by":"crossref","first-page":"49123","DOI":"10.18632\/oncotarget.17097","article-title":"Somatostatin receptor 2A in gliomas: association with oligodendrogliomas and favourable outcome","volume":"8","author":"Kiviniemi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.breast.2026.104946_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122269","article-title":"Tumor-associated macrophages in glioblastoma multiforme-a suitable target for somatostatin receptor-based imaging and therapy?","volume":"10","author":"Lapa","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.breast.2026.104946_bib62","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/jnen\/63.1.13","article-title":"Differential expression of sst1, sst2A, and sst3 somatostatin receptor proteins in low-grade and high-grade astrocytomas","volume":"63","author":"Mawrin","year":"2004","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.breast.2026.104946_bib63","first-page":"817","article-title":"The role of theragnostics in breast cancer: a systematic review of the last 12 years","volume":"19","author":"Balma","year":"2023","journal-title":"Curr Med Imaging"},{"key":"10.1016\/j.breast.2026.104946_bib64","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233408","article-title":"Dotatate PET\/CT and 225Ac-Dotatate therapy for somatostatin receptor\u2013expressing metastatic breast cancer","volume":"312","author":"Ulaner","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.breast.2026.104946_bib65","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104946_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.861434","article-title":"New insights in PRRT: lessons from 2021","volume":"13","author":"Puliani","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.breast.2026.104946_bib67","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","article-title":"Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-Dotatate in the Phase III NETTER-1 trial","volume":"36","author":"Strosberg","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104946_bib68","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104946_bib69","first-page":"3997","article-title":"Expression of somatostatin type-2 and -4 receptor and correlation with histological type in breast cancer","volume":"34","author":"Frati","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.breast.2026.104946_bib70","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10549-005-2414-0","article-title":"Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1\u20135 and correlation with receptor protein expression and tumor pathology","volume":"92","author":"Kumar","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104946_bib71","first-page":"1850","article-title":"Relationship between expression of somatostatin receptors subtype 2 mRNA and estrogen and progesterone receptors in breast cancer","volume":"116","author":"Zeng","year":"2003","journal-title":"Chin Med J"},{"key":"10.1016\/j.breast.2026.104946_bib72","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000049162","article-title":"Management of breast cancer: is there a role for somatostatin and its analogs?","volume":"47","author":"Boccardo","year":"2001","journal-title":"Chemotherapy"},{"key":"10.1016\/j.breast.2026.104946_bib73","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1475-2867-13-93","article-title":"Inhibition of tumor promoting signals by activation of SSTR2 and opioid receptors in human breast cancer cells","volume":"13","author":"Kharmate","year":"2013","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.breast.2026.104946_bib74","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/CAD.0b013e32835a7e29","article-title":"Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162","volume":"24","author":"Seitz","year":"2013","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.breast.2026.104946_bib75","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.mce.2008.01.006","article-title":"Biology of somatostatin in breast cancer","volume":"286","author":"Watt","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.breast.2026.104946_bib76","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000343612","article-title":"Peptide receptor radionuclide therapy (PRRT) in a patient affected by metastatic breast cancer with neuroendocrine differentiation","volume":"7","author":"Savelli","year":"2012","journal-title":"Breast Care"},{"key":"10.1016\/j.breast.2026.104946_bib77","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1097\/RLU.0000000000003005","article-title":"177Lu-DOTATOC peptide receptor radionuclide therapy in a patient with neuroendocrine breast carcinoma and breast invasive ductal carcinoma","volume":"45","author":"Liu","year":"2020","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.breast.2026.104946_bib78","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1073\/pnas.87.18.7235","article-title":"Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers","volume":"87","author":"Garin-Chesa","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.breast.2026.104946_bib79","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.118.215913","article-title":"68Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers","volume":"60","author":"Giesel","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2026.104946_bib80","doi-asserted-by":"crossref","first-page":"36505","DOI":"10.1074\/jbc.274.51.36505","article-title":"Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts","volume":"274","author":"Park","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.breast.2026.104946_bib81","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-019-0770-1","article-title":"Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.breast.2026.104946_bib82","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.220749","article-title":"FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease","volume":"306","author":"Mori","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.breast.2026.104946_bib83","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy","volume":"49","author":"Zboralski","year":"2022","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.breast.2026.104946_bib84","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1016\/j.apsb.2025.07.009","article-title":"Fibroblast activation protein targeting radiopharmaceuticals: from drug design to clinical translation","volume":"15","author":"Wu","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.breast.2026.104946_bib85","series-title":"Anti-fibrotic Drug Discovery: The Royal Society of Chemistry","first-page":"259","article-title":"Intratumoral fibrosis: emerging concepts and therapeutic opportunities","author":"Cremasco","year":"2020"},{"key":"10.1016\/j.breast.2026.104946_bib86","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1158\/1078-0432.CCR-22-1031","article-title":"Cancer-associated fibroblasts in inflammation and antitumor immunity","volume":"29","author":"Kennel","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104946_bib87","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1007\/s00259-020-04990-w","article-title":"A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET\/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy","volume":"48","author":"Ballal","year":"2020","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.breast.2026.104946_bib88","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using 177Lu-FAP-2286: first-in-humans results","volume":"63","author":"Baum","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2026.104946_bib89","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1007\/s00259-026-07766-w","article-title":"Comparative evaluation of [68Ga]Ga-FAP-2286 and [18F]FDG PET\/CT in breast cancer and initial experience with [177Lu]Lu-FAP-2286 therapy","volume":"53","author":"Liu","year":"2026","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.breast.2026.104946_bib90","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00259-023-06482-z","article-title":"Therapeutic potential of [177Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessment","volume":"51","author":"Yadav","year":"2023","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.breast.2026.104946_bib91","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1158\/1078-0432.CCR-24-3918","article-title":"177Lu-LNC1004 radioligand therapy in patients with end-stage metastatic cancers: a single-center, single-arm, Phase II study","volume":"31","author":"Fu","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104946_bib92","first-page":"OF1","article-title":"Targeting fibroblast activation protein with [177Lu]Lu-FAP-2286 in patients with advanced solid tumors in the phase I LuMIERE trial","author":"McConathy","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104946_bib93","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1007\/s00259-024-06817-4","article-title":"The complete metabolic\/molecular response to chemotherapy combined with [177Lu]Lu-FAP-2286 in metastatic breast cancer","volume":"51","author":"Banihashemian","year":"2024","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.breast.2026.104946_bib94","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.2967\/jnumed.124.269444","article-title":"A vision for gastrin-releasing peptide receptor targeting for imaging and therapy: perspective from academia and industry","volume":"66","author":"Morgat","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2026.104946_bib95","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2967\/jnumed.116.188011","article-title":"Expression of gastrin-releasing peptide receptor in breast cancer and its association with pathologic, biologic, and clinical parameters: a study of 1,432 primary tumors","volume":"58","author":"Morgat","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2026.104946_bib96","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/bjc.1991.204","article-title":"Bombesin stimulates proliferation of human breast cancer cells in culture","volume":"63","author":"Nelson","year":"1991","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2026.104946_bib97","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2967\/jnumed.107.045054","article-title":"Bombesin receptor antagonists may be preferable to agonists for tumor targeting","volume":"49","author":"Cescato","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2026.104946_bib98","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.canlet.2008.05.044","article-title":"Osteotropic cancers: from primary tumor to bone","volume":"273","author":"Buijs","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.breast.2026.104946_bib99","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s13139-017-0509-2","article-title":"Treatment of bone metastasis with bone-targeting radiopharmaceuticals","volume":"52","author":"Choi","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.breast.2026.104946_bib100","first-page":"1358","article-title":"Radiopharmaceutical therapy for palliation of bone pain from osseous metastases","volume":"45","author":"Pandit-Taskar","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2026.104946_bib101","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1148\/radiology.134.1.6153129","article-title":"Evaluation of radioactive phosphorus in the palliation of metastatic bone lesions from carcinoma of the breast and prostate","volume":"134","author":"Cheung","year":"1980","journal-title":"Radiology"},{"key":"10.1016\/j.breast.2026.104946_bib102","first-page":"217","article-title":"Radiophosphorous (P32) treatment in carcinoma of the breast and prostate: report of 39 cases","volume":"74","author":"Miller","year":"1974","journal-title":"J Am Osteopath Assoc"},{"key":"10.1016\/j.breast.2026.104946_bib103","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0001-2998(05)80153-9","article-title":"Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous metastases","volume":"22","author":"Silberstein","year":"1992","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.breast.2026.104946_bib104","article-title":"Beyond palliation: therapeutic applications of 153samarium-EDTMP","volume":"3","author":"Breelyn","year":"2013","journal-title":"Clin Exp Pharmacol"},{"key":"10.1016\/j.breast.2026.104946_bib105","first-page":"35","article-title":"Efficacy and toxicity of 153samarium-EDTMP in painful breast cancer bone metastases","volume":"32","author":"Dolezal","year":"2009","journal-title":"Onkologie"},{"key":"10.1016\/j.breast.2026.104946_bib106","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1053-4296(00)80047-8","article-title":"Use of radionuclides for the palliation of bone metastases","volume":"10","author":"McEwan","year":"2000","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.breast.2026.104946_bib107","first-page":"321","article-title":"Efficacy of 153Sm-EDTMP on bone pain palliation in metastatic patients: breast and prostate cancers","volume":"10","author":"Rokni","year":"2023","journal-title":"Front Biomed Technol"},{"key":"10.1016\/j.breast.2026.104946_bib108","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13063-019-3643-6","article-title":"CApecitabine plus Radium-223 (XofigoTM) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB\/IIA randomised controlled trial","volume":"21","author":"Coleman","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.breast.2026.104946_bib109","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1158\/1078-0432.CCR-04-2244","article-title":"First clinical experience with \u03b1-emitting radium-223 in the treatment of skeletal metastases","volume":"11","author":"Nilsson","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104946_bib110","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10549-023-07147-z","article-title":"Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials","volume":"204","author":"Rugo","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104946_bib111","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/cam4.2780","article-title":"Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer","volume":"9","author":"Ueno","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.breast.2026.104946_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2022.100442","article-title":"A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo\u2122) in breast cancer patients with BONe metastases: CARBON trial results","volume":"35","author":"Winter","year":"2022","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.breast.2026.104946_bib113","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.3390\/cancers12092390","article-title":"Diagnosis and treatment of bone metastases in breast cancer: radiotherapy, local approach and systemic therapy in a guide for clinicians","volume":"12","author":"Marazzi","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.breast.2026.104946_bib114","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3390\/cancers17030456","article-title":"Unveiling prostate-specific membrane antigen's potential in breast cancer management","volume":"17","author":"Motta","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.breast.2026.104946_bib115","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1055\/a-1638-9429","article-title":"Expression of prostate specific membrane antigen (PSMA) in breast cancer","volume":"82","author":"Unger","year":"2022","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1016\/j.breast.2026.104946_bib116","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.2967\/jnumed.123.266659","article-title":"Frequent amplification and overexpression of PSMA in basallike breast cancer from analysis of the Cancer Genome Atlas","volume":"65","author":"Zhou","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2026.104946_bib117","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1007\/s00259-025-07667-4","article-title":"PSMA-targeted PET imaging in patients with metastatic triple-negative breast cancer: results of the prospective PRISMA trial","volume":"53","author":"Manley","year":"2025","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.breast.2026.104946_bib118","doi-asserted-by":"crossref","first-page":"30146","DOI":"10.18632\/oncotarget.25731","article-title":"Identification of integrin drug targets for 17 solid tumor types","volume":"9","author":"Arun","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.breast.2026.104946_bib119","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41573-021-00284-4","article-title":"Emerging therapeutic opportunities for integrin inhibitors","volume":"21","author":"Slack","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.breast.2026.104946_bib120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: biological implications and therapeutic opportunities","volume":"10","author":"Desgrosellier","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.breast.2026.104946_bib121","first-page":"152","article-title":"First-in-human study demonstrating tumor-angiogenesis by PET\/CT imaging with 68Ga-NODAGA-THERANOST, a high-affinity peptidomimetic for \u03b1v\u03b23 integrin receptor targeting","volume":"30","author":"Baum","year":"2015","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.breast.2026.104946_bib122","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2174\/187152010794728639","article-title":"Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation","volume":"10","author":"Mas-Moruno","year":"2010","journal-title":"Anti Cancer Agents Med Chem"},{"key":"10.1016\/j.breast.2026.104946_bib123","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.3390\/ijms26073143","article-title":"Integrins in cancer drug resistance: molecular mechanisms and clinical implications","volume":"26","author":"Kariya","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.breast.2026.104946_bib124","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3390\/biomedicines12061163","article-title":"The role of \u03b1v\u03b23 integrin in cancer therapy resistance","volume":"12","author":"Pachane","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.breast.2026.104946_bib125","article-title":"Carbonic anhydrase IX-related tumoral hypoxia predicts worse prognosis in breast cancer: a systematic review and meta-analysis","volume":"10","author":"Numprasit","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.breast.2026.104946_bib126","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13000-023-01325-9","article-title":"The relationship between carbonic anhydrase IX (CAIX) and patient survival in breast cancer: systematic review and meta-analysis","volume":"18","author":"Shamis","year":"2023","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.breast.2026.104946_bib127","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1007\/s00259-026-07783-9","article-title":"CAIX-targeted radiotracer for diagnosis and monitoring VEGFR-TKI response in clear cell renal cell carcinoma","volume":"53","author":"Guo","year":"2026","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.breast.2026.104946_bib128","first-page":"2585","article-title":"Cellular and radiobiological effects of carbonic anhydrase IX in human breast cancer cells","volume":"41","author":"G\u00fcttler","year":"2019","journal-title":"Oncol Rep"},{"key":"10.1016\/j.breast.2026.104946_bib129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/metabo8010013","article-title":"Carbonic anhydrase IX (CAIX), cancer, and radiation responsiveness","volume":"8","author":"Ward","year":"2018","journal-title":"Metabolites"},{"key":"10.1016\/j.breast.2026.104946_bib130","doi-asserted-by":"crossref","first-page":"24856","DOI":"10.18632\/oncotarget.4498","article-title":"Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of\u00a0in vitro\u00a0breast cancer models","volume":"6","author":"Ward","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.breast.2026.104946_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103838","article-title":"Targeted therapeutic strategies for Nectin-4 in breast cancer: recent advances and future prospects","volume":"79","author":"Wang","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104946_bib132","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.2024.42.16_suppl.570","article-title":"Nectin-4 expression in primary breast cancer and associated clinical outcomes","volume":"42","author":"Medford","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104946_bib133","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","article-title":"B7-H3: an attractive target for antibody-based immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104946_bib134","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41422-018-0060-4","article-title":"Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth","volume":"28","author":"Yang","year":"2018","journal-title":"Cell Res"},{"key":"10.1016\/j.breast.2026.104946_bib135","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10549-014-2988-5","article-title":"Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer","volume":"146","author":"Muenst","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104946_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2020.105834","article-title":"Ether lipid and sphingolipid expression patterns are estrogen receptor-dependently altered in breast cancer cells","volume":"127","author":"Hahnefeld","year":"2020","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.breast.2026.104946_bib137","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ajpath.2010.11.005","article-title":"Role of cholesterol in the development and progression of breast cancer","volume":"178","author":"Llaverias","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.breast.2026.104946_bib138","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/imm.12617","article-title":"Lipid rafts in immune signalling: current progress and future perspective","volume":"149","author":"Varshney","year":"2016","journal-title":"Immunology"},{"key":"10.1016\/j.breast.2026.104946_bib139","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111652","article-title":"A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety","volume":"9","author":"Grudzinski","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.breast.2026.104946_bib140","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/07357907.2015.1081691","article-title":"A Phase 1, multi-center, open-label, dose-escalation study of\u00a0131I-CLR1404 in subjects with relapsed or refractory advanced solid malignancies","volume":"33","author":"Lubner","year":"2015","journal-title":"Cancer Invest"},{"key":"10.1016\/j.breast.2026.104946_bib141","first-page":"224","article-title":"Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy","volume":"1815","author":"Mukhopadhyay","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.breast.2026.104946_bib142","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.semnuclmed.2004.12.001","article-title":"Radioimmunodetection and therapy of breast cancer","volume":"35","author":"DeNardo","year":"2005","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.breast.2026.104946_bib143","article-title":"High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial","volume":"55","author":"Schrier","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2026.104946_bib144","first-page":"1180","article-title":"Radioimmunotherapy for breast cancer using indium-111\/yttrium-90 BrE-3: results of a phase I clinical trial","volume":"38","author":"DeNardo","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2026.104946_bib145","series-title":"Basic radiation oncology","author":"Beyzadeoglu","year":"2022"},{"key":"10.1016\/j.breast.2026.104946_bib146","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2174\/187152007781058596","article-title":"Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases","volume":"7","author":"Lam","year":"2007","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.breast.2026.104946_bib147","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1470-2045(05)70206-0","article-title":"Radioisotopes for the palliation of metastatic bone cancer: a systematic review","volume":"6","author":"Finlay","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104946_bib148","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ctrv.2011.05.008","article-title":"Radionuclide treatment of painful bone metastases in patients with breast cancer: a systematic review","volume":"38","author":"Christensen","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2026.104946_bib149","doi-asserted-by":"crossref","DOI":"10.18103\/mra.v9i4.2388","article-title":"An update on toxicity of therapeutic radionuclides","volume":"9","author":"Vallathol","year":"2021","journal-title":"Med Res Arch"},{"key":"10.1016\/j.breast.2026.104946_bib150","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0146645319838665","article-title":"ICRP publication 140: radiological protection in therapy with radiopharmaceuticals","volume":"48","author":"Yonekura","year":"2019","journal-title":"Ann ICRP"},{"key":"10.1016\/j.breast.2026.104946_bib151","series-title":"ALARA principle","year":"2025"},{"key":"10.1016\/j.breast.2026.104946_bib152","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/pro6.1239","article-title":"Revolutionizing cancer treatment: the role of radiopharmaceuticals in modern cancer therapy","volume":"8","author":"Varghese","year":"2024","journal-title":"Precis Radiat Oncol"},{"key":"10.1016\/j.breast.2026.104946_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102524","article-title":"Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer","volume":"115","author":"Calais","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2026.104946_bib154","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6780","article-title":"Establishing a robust radioligand therapy program: a practical approach for North American centers","volume":"13","author":"Mittra","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.breast.2026.104946_bib155","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1007\/s00259-024-06657-2","article-title":"Guiding principles on the education and practice of theranostics","volume":"51","author":"Pascual","year":"2024","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.breast.2026.104946_bib156","first-page":"39","article-title":"Multidisciplinary breast cancer teams and proposed standards","volume":"31","author":"G\u00fcler","year":"2015","journal-title":"Ulusal Cerrahi Dergisi"},{"key":"10.1016\/j.breast.2026.104946_bib157","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.semradonc.2024.07.006","article-title":"The history and future of multidisciplinary cancer care","volume":"34","author":"LaVigne","year":"2024","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.breast.2026.104946_bib158","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000528280","article-title":"Review article a multidisciplinary evaluation for advanced supportive care of breast cancer patients","volume":"18","author":"Petrone","year":"2023","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.breast.2026.104946_bib159","first-page":"79","article-title":"Benefits of multidisciplinary teamwork in the management of breast cancer","volume":"5","author":"Taylor","year":"2013","journal-title":"Breast Cancer"},{"key":"10.1016\/j.breast.2026.104946_bib160","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1007\/s00259-022-05785-x","article-title":"Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre","volume":"49","author":"Herrmann","year":"2022","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.breast.2026.104946_bib161","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2214\/AJR.22.28237","article-title":"Integrating theranostics into patient care pathways: AJR Expert Panel narrative review","volume":"220","author":"O'Shea","year":"2023","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.breast.2026.104946_bib162","first-page":"216","article-title":"[PSMA radioligand therapy could pose infrastructural challenges for nuclear medicine: results of a basic calculation for the capacity planning of nuclear medicine beds in the German hospital sector]","volume":"60","author":"Zippel","year":"2021","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.breast.2026.104946_bib163","doi-asserted-by":"crossref","DOI":"10.1002\/acm2.13899","article-title":"Logistical, technical, and radiation safety aspects of establishing a radiopharmaceutical therapy program: a case in Lutetium-177 prostate-specific membrane antigen (PSMA) therapy","volume":"24","author":"Zoberi","year":"2023","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.breast.2026.104946_bib164","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00259-020-04745-7","article-title":"Realising the potential of radioligand therapy: policy solutions for the barriers to implementation across Europe","volume":"47","author":"Merkel","year":"2020","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.breast.2026.104946_bib165","series-title":"Concept paper on clinical evaluation of therapeutic radiopharmaceuticals in oncology","year":"2025"},{"key":"10.1016\/j.breast.2026.104946_bib166","doi-asserted-by":"crossref","first-page":"700","DOI":"10.2967\/jnumed.123.266847","article-title":"Human epidermal growth factor receptor 2 (HER2) PET imaging of HER2-low breast cancer with [68Ga]Ga-ABY-025: results from a pilot study","volume":"65","author":"Altena","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2026.104946_bib167","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae188","article-title":"Impact of HER2-targeted PET\/CT imaging in patients with breast cancer and therapeutic response monitoring","volume":"30","author":"Gui","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2026.104946_bib168","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.115.157909","article-title":"Molecular imaging of biomarkers in breast cancer","volume":"57","author":"Ulaner","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2026.104946_bib169","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2967\/jnumed.120.248062","article-title":"Combination strategies to improve targeted radionuclide therapy","volume":"61","author":"Chan","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.breast.2026.104946_bib170","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3390\/pharmaceutics13050674","article-title":"Combination therapy, a promising approach to enhance the efficacy of radionuclide and targeted radionuclide therapy of prostate and breast cancer","volume":"13","author":"Damiana","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.breast.2026.104946_bib171","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3390\/ph17081031","article-title":"Future treatment strategies for cancer patients combining targeted alpha therapy with pillars of cancer treatment: external beam radiation therapy, checkpoint inhibition immunotherapy, cytostatic chemotherapy, and brachytherapy","volume":"17","author":"Winter","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.breast.2026.104946_bib172","volume":"vol. 45","author":"Corti","year":"2025"},{"key":"10.1016\/j.breast.2026.104946_bib173","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2147\/ITT.S485643","article-title":"Combination of radioligand therapy and immunotherapy: how to make it work in clinic?","volume":"14","author":"Jiao","year":"2025","journal-title":"ImmunoTargets Ther"},{"key":"10.1016\/j.breast.2026.104946_bib174","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1053\/j.semnuclmed.2024.05.011","article-title":"Combination strategies and targeted radionuclide therapies","volume":"54","author":"Jewell","year":"2024","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.breast.2026.104946_bib175","doi-asserted-by":"crossref","first-page":"7948","DOI":"10.7150\/thno.39203","article-title":"Integrin \u03b1v\u03b23-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy","volume":"9","author":"Chen","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.breast.2026.104946_bib176","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2967\/jnumed.120.246041","article-title":"Immune-Checkpoint blockade Enhances\u00a0225Ac-PSMA617 efficacy in a mouse model of prostate cancer","volume":"62","author":"Czernin","year":"2021","journal-title":"J Nucl Med"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:57:40Z","timestamp":1792789060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626002560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":176,"alternative-id":["S0960977626002560"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104946","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current state and future potential of radiopharmaceutical therapy in breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104946","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104946"}}